Roche (ROG) Pharma Day 2026 summary

Strategic progress and future growth

• Achieved strong operational efficiency and financial performance, with HY 2026 sales up 6% and core operating profit (COP) up 10% compared to the previous year.

• R&D cycle times shortened by ~19 months since YE 2023, with portfolio value up 93% and 11 new assets added in 2026.

• Up to 20 new molecular entities (NMEs) targeted for launch by 2030, with major late-stage readouts expected from 2027 to 2030 in areas such as IBD, Alzheimer's, MASH, Parkinson's, obesity, and hypertension.

• No patent cliff anticipated; on-market portfolio and pipeline expected to drive sustained growth beyond 2030.

• Mid- to high-single digit sales growth and COP growth ahead of sales projected for the coming years.

R&D and portfolio transformation

• Introduction of the “Bar” framework led to a 72% increase in total portfolio value since YE 2023 and a shift to higher-value, lower-risk assets.

• Ph III success rate improved to over 80% in 2026 YTD, with 47 assets added since 2024 through early R&D and partnerships.

• Strategic external innovation through acquisitions and partnerships, including deals with Alnylam, Carmot, Telavant, and others, to rejuvenate the pipeline.

• R&D savings of CHF ~2bn reallocated to transformative programs and productivity initiatives by YE 2026.

• AI and digitalization embedded across R&D, manufacturing, and commercialization, including Lab-in-the-Loop and digital twin manufacturing platforms.

Therapeutic area focus and pipeline highlights

• Five core therapeutic areas (Oncology/Hematology, Neurology, Immunology, Ophthalmology, CVRM) cover 60% of global disease burden.

• Oncology/Hematology: Positive Ph III readouts for giredestrant (HR+ breast cancer), divarasib (KRAS G12C NSCLC), and others; advancing best-in-class assets and novel modalities.

• Neurology: Fenebrutinib filed in RMS/PPMS, trontinemab in Ph III for Alzheimer's, prasinezumab in Ph III for Parkinson's; Enspryng filed for MOGAD and TED.

• Immunology: Gazyva filed for SLE and MN, sefaxersen positive Ph III in IgAN, afimkibart Ph III in IBD, and p40xTL1A bispecific in Ph II for UC.

• Ophthalmology: Vabysmo continues global share gains, VEGF x IL6 DutaFab moving to Ph III in DME, vamikibart filed in UME, Susvimo approved in EU for nAMD.

• CVRM: Enicepatide and petrelintide advancing in obesity and T2D, zilebesiran in Ph III for hypertension, pegozafermin in Ph III for MASH.